Risk stratification and treatment goals in pulmonary arterial hypertension

Area of Science:

• Cardiology
• Pulmonology
• Medical Diagnostics

Background:

• Risk stratification is crucial for predicting outcomes in pulmonary arterial hypertension (PAH).
• Current tools rely on noninvasive parameters like functional class, 6-minute walk distance, and natriuretic peptides.
• These parameters have limitations in accurately reflecting PAH severity for individual treatment decisions.

Purpose of the Study:

• To evaluate the adequacy of current risk stratification tools in PAH.
• To explore the potential of novel markers for guiding individualized PAH treatment.
• To assess the added value of invasive hemodynamics and cardiac imaging in PAH management.

Main Methods:

• Review of current validated risk stratification tools for PAH.
• Analysis of prognostic factors including noninvasive and invasive parameters.
• Consideration of emerging therapies and their impact on treatment guidance.

Main Results:

• Noninvasive parameters are key but may lack specificity for guiding individual PAH treatment.
• Pulmonary vascular remodeling markers are gaining relevance with new combination therapies.
• Preliminary data suggest invasive hemodynamics and cardiac imaging provide incremental value.

Conclusions:

• While low mortality risk is a goal, current noninvasive methods may not suffice for personalized PAH treatment.
• Invasive hemodynamics and cardiac imaging show promise in refining treatment strategies.
• Further research is needed to integrate these advanced methods into routine PAH care.